Rendering

Component: (Network and Table)
Network
2308301 - Disclosure - Equity Compensation Plans (Tables)
(http://www.apricusbio.com/role/EquityCompensationPlansTables)
Table(Implied)
Slicers (applies to each fact value in each table cell)
Reporting Entity [Axis]0001017491 (http://www.sec.gov/CIK)
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]Period [Axis]
2016-01-01 - 2016-12-31
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
 
Summary of Stock Option Activity
A summary of stock option activity during the year ended December 31, 2016 is as follows:
 
Number of
Shares
 
Weighted
Average
Exercise
Price
 
Weighted
Average Remaining
Contractual
Life (in years)
 
Total
Aggregate
Intrinsic
Value
Outstanding as of December 31, 2015
405,348

 
$
19.46

 
8.2

 
$
—

Granted
166,695

 
10.57

 
—

 
—

Cancelled
(157,178
)
 
15.92

 
—

 
—

Outstanding as of December 31, 2016
414,865

 
$
17.23

 
7.6

 
$
—

Vested and expected to vest as of December 31, 2016
391,010

 
$
17.54

 
7.5

 
$
—

Exercisable as of December 31, 2016
228,392

 
$
20.88

 
6.7

 
$
—

  
Schedule of Restricted Stock Units Activity
A summary of restricted stock unit activity during the year ended December 31, 2016 is as follows:
 
Number of
Shares
 
Weighted Average Grant Date Fair Value
Nonvested as of December 31, 2015
$
—

 
$
—

Granted
143,416

 
$
5.29

Vested
(17,842
)
 
$
5.86

Forfeited
(10,459
)
 
$
6.28

Nonvested as of December 31, 2016
$
115,115

 
$
5.11

  
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions
The following table presents the weighted average assumptions used by the Company to estimate the fair value of stock option grants using the Black-Scholes option-pricing model, as well as the resulting weighted average fair values at their issuance dates during the years ended December 31, 2016 and 2015:
 
Year Ended December 31,
 
2016
 
2015
Risk-free interest rate
1.36%-1.78%

 
1.37% - 1.87%

Volatility
72.35%-80.02%

 
66.85%-101.54%

Dividend yield
—
%
 
—
%
Expected term
5.25-6.08 years

 
5.25- 6.46 years

Forfeiture rate
11.33
%
 
11.54
%
Weighted average fair value
$
7.23

 
$
10.67

  
Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan
The following table summarizes the total stock-based compensation expense resulting from share-based awards recorded in the Company’s consolidated statements of operations (in thousands):
 
 
Year Ended December 31,
 
 
2016
 
2015
Research and development
 
$
534

 
$
199

General and administrative
 
1,213

 
1,011

 
 
$
1,747

 
$
1,210